Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway

被引:45
作者
Zhou, Ping [1 ]
Qian, Liping [1 ]
Chou, Tsu [1 ]
Iadecola, Costantino [1 ]
机构
[1] Cornell Univ, Weill MEd Coll, Div Neurobiol, New York, NY 10021 USA
关键词
hippocampal slice culture; oxygen glucose deprivation; AKT; PTEN; neuroprotection; BAD; EP1; receptors;
D O I
10.1016/j.nbd.2007.11.010
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The prostanoid synthesizing enzyme cyclooxygenase-2 (COX-2) is involved in the mechanisms of cerebral ischemia, an effect mediated by prostaglandin E2 through activation of EP1 receptors. Thus, inhibition of EP1 receptors is neuroprotective in models of ischemic stroke, but the molecular mechanisms of the effect have not been fully elucidated. We used oxygen glucose deprivation (OGD) in hippocampal slices as an injury model to investigate whether the neuroprotection afforded by EP1 receptor inhibition involves the PI3K/AKT survival pathway. EP1 receptor inhibition with SC51089 or SC51322 reduced the hippocampal damage produced by ODG by 28 +/- 2% and 32 +/- 3%, respectively (p<0.05). OGD induced a transient reduction of AKT activity that was partly counteracted by SC51089. LY294002 blocked the increase in phospho-AKT evoked by SC51089 and abolished the associated protective effect. The AKT activation induced by SC51089 was associated with phosphorylation of PTEN, the phosphatase that negatively regulates AKT. Furthermore, SC51089 attenuated the mitochondrial translocation of the proapoptotic protein BAD. These data indicate that EP1 receptor inhibition improves the survival of hippocampal slices by preventing the attenuation in AKT activity induced by OGD, and by reducing the mitochondrial translocation of BAD. The findings provide evidence for a link between EP1 receptors and the PI3K/AKT survival pathway and shed light on the molecular mechanisms of the prosurvival effect of EP1 receptor inhibition. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:543 / 551
页数:9
相关论文
共 27 条
[1]   Prostanoid receptors: Subtypes and signaling [J].
Breyer, RM ;
Bagdassarian, CK ;
Myers, SA ;
Breyer, MD .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2001, 41 :661-690
[2]   Neuroprotection of cultured cortical neurons mediated by the cyclooxygenase-2 inhibitor APHS can be reversed by a prostanoid [J].
Carlson, NG .
JOURNAL OF NEUROSCIENCE RESEARCH, 2003, 71 (01) :79-88
[3]   Cyclo-oxygenase-2 messenger RNA induction in focal cerebral ischemia [J].
CollacoMoraes, Y ;
Aspey, B ;
Harrison, M ;
deBelleroche, J .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1996, 16 (06) :1366-1372
[4]   14-3-3 proteins and survival kinases cooperate to inactivate BAD by BH3 domain phosphorylation [J].
Datta, SR ;
Katsov, A ;
Hu, L ;
Petros, A ;
Fesik, SW ;
Yaffe, MB ;
Greenberg, ME .
MOLECULAR CELL, 2000, 6 (01) :41-51
[5]   Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery [J].
Datta, SR ;
Dudek, H ;
Tao, X ;
Masters, S ;
Fu, HA ;
Gotoh, Y ;
Greenberg, ME .
CELL, 1997, 91 (02) :231-241
[6]   The phosphoinositide (PI) 3-kinase family [J].
Foster, FM ;
Traer, CJ ;
Abraham, SM ;
Fry, MJ .
JOURNAL OF CELL SCIENCE, 2003, 116 (15) :3037-3040
[7]  
Henshall DC, 2002, J NEUROSCI, V22, P8458
[8]   PI3K inhibition in neonatal rat brain slices during and after hypoxia reduces phospho-Akt and increases cytosolic cytochrome c and apoptosis [J].
Hirai, K ;
Hayashi, T ;
Chan, PH ;
Zeng, JY ;
Yang, GY ;
Basus, VJ ;
James, TL ;
Litt, L .
MOLECULAR BRAIN RESEARCH, 2004, 124 (01) :51-61
[9]   The bad guy cooperates with good cop p53: Bad is transcriptionally up-regulated by p53 and forms a bad/p53 complex at the mitochondria to induce apoptosis [J].
Jiang, Peng ;
Du, Wenjing ;
Heese, Klaus ;
Wu, Mian .
MOLECULAR AND CELLULAR BIOLOGY, 2006, 26 (23) :9071-9082
[10]   Bad as a converging signaling molecule between survival PI3-K/Akt and death JNK in neurons after transient focal cerebral ischemia in rats [J].
Kamada, Hiroshi ;
Nito, Chikako ;
Endo, Hidenori ;
Chan, Pak H. .
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2007, 27 (03) :521-533